TW200397B - - Google Patents

Download PDF

Info

Publication number
TW200397B
TW200397B TW081104701A TW81104701A TW200397B TW 200397 B TW200397 B TW 200397B TW 081104701 A TW081104701 A TW 081104701A TW 81104701 A TW81104701 A TW 81104701A TW 200397 B TW200397 B TW 200397B
Authority
TW
Taiwan
Prior art keywords
acid
day
patent application
calcium
gla
Prior art date
Application number
TW081104701A
Other languages
English (en)
Chinese (zh)
Original Assignee
Efamol Holdings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Efamol Holdings filed Critical Efamol Holdings
Application granted granted Critical
Publication of TW200397B publication Critical patent/TW200397B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW081104701A 1991-06-05 1992-06-16 TW200397B (https=)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919112052A GB9112052D0 (en) 1991-06-05 1991-06-05 Fatty acid treatment

Publications (1)

Publication Number Publication Date
TW200397B true TW200397B (https=) 1993-02-21

Family

ID=10696108

Family Applications (1)

Application Number Title Priority Date Filing Date
TW081104701A TW200397B (https=) 1991-06-05 1992-06-16

Country Status (14)

Country Link
US (1) US5318991A (https=)
EP (1) EP0517425A1 (https=)
JP (1) JPH05178744A (https=)
KR (1) KR930000114A (https=)
AU (1) AU659456B2 (https=)
CA (1) CA2070468A1 (https=)
FI (1) FI922582A7 (https=)
GB (1) GB9112052D0 (https=)
IE (1) IE921806A1 (https=)
NO (1) NO302100B1 (https=)
NZ (1) NZ242897A (https=)
SG (1) SG49682A1 (https=)
TW (1) TW200397B (https=)
ZA (1) ZA923915B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9217780D0 (en) * 1992-08-21 1992-10-07 Efamol Holdings Fatty acid treatment
US5888541A (en) * 1992-08-21 1999-03-30 Scotia Holdings Plc Fatty acid treatment
US5516801A (en) * 1992-08-21 1996-05-14 Scotia Holdings Plc Fatty acid treatment for ectopic calcium deposition
GB9217781D0 (en) * 1992-08-21 1992-10-07 Efamol Holdings Fatty acid treatment
AU683027B2 (en) * 1993-01-27 1997-10-30 Scotia Holdings Plc Triglycerides
FR2704390B1 (fr) * 1993-04-29 1995-06-02 Boiron Complément nutritionnel absorbable per-os destiné à améliorer la peau.
ATE186174T1 (de) * 1993-08-20 1999-11-15 Nestle Sa Lipidzusammensetzung für nahrungsmittel
US5668174A (en) * 1993-12-29 1997-09-16 Kowa Tekuno Sachi Co., Ltd. Method of treating hyperparathyroidism
EP0711503A3 (en) * 1994-11-14 1997-11-26 Scotia Holdings Plc Milk fortified with GLA and/or DGLA
US5804210A (en) * 1996-08-07 1998-09-08 Wisconsin Alumni Research Foundation Methods of treating animals to maintain or enhance bone mineral content and compositions for use therein
AU8857298A (en) * 1997-07-16 1999-02-10 Societe Des Produits Nestle S.A. Method for prophylaxis or treatment of bone density loss
US6479545B1 (en) * 1999-09-30 2002-11-12 Drugtech Corporation Formulation for menopausal women
WO2002074308A1 (en) * 2001-03-15 2002-09-26 Roche Vitamins Ag Composition for the prevention of osteoporosis comprising a combination of isoflavones and polyunsaturated fatty acids
US6576667B2 (en) * 2001-11-14 2003-06-10 Norel Acquisition Corp. Method for manufacturing fatty acid calcium salts from high glyceride content oils
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
US8728546B1 (en) 2013-03-15 2014-05-20 Swing Aerobics Licensing, Inc. Medicament for treatment of cancer, cardiovascular diseases and inflammation
ES2784240T3 (es) * 2014-06-04 2020-09-23 Ds Biopharma Ltd Composiciones farmacéuticas que comprenden DGLA y uso de las mismas
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1417119A (en) * 1972-11-30 1975-12-10 Thiele G H Process for treating bones
DE3474633D1 (en) * 1984-02-01 1988-11-24 Tpo Pharmachim Means for the treatment and the prophylaxis of uratic and mixed uratic lithiasis
GB8621816D0 (en) * 1986-09-10 1986-10-15 Efamol Ltd Therapeutic composition
JPH0625057B2 (ja) * 1987-12-14 1994-04-06 日本油脂株式会社 骨形成促進剤
US4855736A (en) * 1988-06-03 1989-08-08 Hsu Chi Heng Electronic parking sensor apparatus
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
GB9001121D0 (en) * 1990-01-18 1990-03-21 Efamol Holdings Efa compositions and therapy
GB9002048D0 (en) * 1990-01-30 1990-03-28 Efamol Holdings Essential fatty acid compositions and treatments

Also Published As

Publication number Publication date
FI922582A0 (fi) 1992-06-04
FI922582L (fi) 1992-12-06
AU1726692A (en) 1992-12-10
CA2070468A1 (en) 1992-12-06
JPH05178744A (ja) 1993-07-20
NO922214L (no) 1992-12-07
US5318991A (en) 1994-06-07
NO302100B1 (no) 1998-01-26
EP0517425A1 (en) 1992-12-09
AU659456B2 (en) 1995-05-18
ZA923915B (en) 1993-02-24
NO922214D0 (no) 1992-06-04
FI922582A7 (fi) 1992-12-06
NZ242897A (en) 1997-06-24
IE921806A1 (en) 1992-12-16
KR930000114A (ko) 1993-01-15
GB9112052D0 (en) 1991-07-24
SG49682A1 (en) 1998-06-15

Similar Documents

Publication Publication Date Title
TW200397B (https=)
TW323230B (https=)
CN100469363C (zh) 脂肪酸的治疗组合物
CA1261274A (en) Pharmaceutical and dietary compositions
US5888541A (en) Fatty acid treatment
JP3065710B2 (ja) 抗炎症剤
AU2001274276A1 (en) Therapeutic combinations of fatty acids
JPS6038324A (ja) 脂肪酸組成物
US4898885A (en) Pharmaceutica and dietary compositions
WO1998048788A1 (en) Treatment of depression and anxiety using docosahexaenoic acid or natural antioxidants
JPH0761954B2 (ja) コレステロール低下または上昇抑制剤
CA1334002C (en) Essential fatty acid compositions and methods for the modulation of prostaglandin levels in mammals
FR2649322A1 (fr) Complexes biodisponibles d'acide (alpha)-linolenique, extraits de plantes en contenant et compositions pharmaceutiques les incorporant
JP2002505279A (ja) 癌管理
CA1309352C (en) Method and composition for reducing serum cholesterol
JP2000086425A (ja) 美白剤およびこれを配合してなる美白用組成物
HK1012580A (en) Fatty acids for the reduction of urinary calcium excretion and the treatment of osteoporosis
HK1000997B (en) Use of fatty acids for increasing gut calcium absorption
HK1050486B (en) Therapeutic combinations of fatty acids